Reprogramming Protein Homeostasis: Lyterian’s Patient-Focused Mission to Rethink Oncology and Neurodegeneration

The challenge of treating cancer and neurodegenerative disorders is as much about biology as it is about patient care. Both are complex, multifactorial diseases with layers of mutations and pathways that frustrate one-size-fits-all approaches. Many patients today face invasive therapies, modest benefits, or years of clinical uncertainty.

Ingrid Wertz, CEO of Lyterian Therapeutics, believes it doesn’t have to stay this way. “Our goal is to end disease in patients,” she says. “That could mean curing them outright, or it could mean transforming disease into something manageable—so patients live with it, not die from it.”

It’s a bold framing for a company that only launched in late 2022. Yet behind the ambitious language is a grounded approach: build therapies that work on genetically validated, patient-derived disease drivers, and design them as orally accessible small molecules that can reach patients around the globe.

Building a Vision from Genetic Ground Truths

Lyterian begins where biology is clearest: with genetic validation. Wertz emphasizes that the company focuses on proteins where human evidence—not just animal models—shows clear pathogenicity.

“In oncology, you see mutations that turn proteins on or stabilize them abnormally. In neurodegeneration, mutations push proteins from normal to disease states. These changes are validated in patients, and that’s where we concentrate,” she explains.

This prioritization means Lyterian avoids chasing every new signal. Instead, it doubles down on validated drivers—proteins that have been tied to disease progression in people and often reinforced through clinical or therapeutic data. The approach may be slower, but it provides a surer footing for advancing therapies toward the clinic.

Molecular Glues: A Simpler Route to Complex Biology

Central to Lyterian’s strategy is the molecular glue concept. Unlike larger, engineered molecules designed to forcibly tether two proteins, Lyterian develops ligands that subtly “nudge” disease-causing proteins into contact with protein Z, a regulator in the ubiquitin–proteasome system.

“Think of it as increasing the chance encounter,” Wertz says. “Even if proteins associate only a little more often, it makes it far easier for regulatory machinery to act.”

This simplicity matters. Bifunctional degraders are powerful but notoriously difficult to deliver and manufacture. By contrast, Lyterian’s glue compounds are smaller, more drug-like, and orally bioavailable—qualities that make them better suited for widespread use, especially outside major medical centers.

What Are Molecular Glues?
Molecular glues are small molecules that encourage two proteins to interact. Unlike “bifunctional degraders,” which have two arms designed to bind two targets at once, glues work more subtly. By raising the probability of contact between a disease-causing protein and the body’s regulatory machinery, they promote degradation or correction without the bulk or complexity of larger molecules.

• Analogy: Like a social matchmaker who brings two people into the same room rather than handcuffing them together.
• Why it matters: Glues are easier to deliver, more scalable to manufacture, and potentially usable across a wider range of diseases.

AI: From Structural Prediction to Practical Acceleration

While molecular glues provide the platform, artificial intelligence is the amplifier. Lyterian integrates AI at multiple stages:

• Binding assays: Machine learning distinguishes positive and negative interactions from carefully designed controls.
• Protein movement: Techniques like hydrogen–deuterium exchange feed data into models that account for dynamic, not just static, protein structures.
• Virtual screening: AI helps identify cryptic drug pockets that only emerge when proteins “breathe” or shift conformation.
• AlphaFold integration: Predictions guide Lyterian to focus on structured, druggable domains while deprioritizing unstructured regions.

“We can’t try everything—it’s too expensive,” Wertz notes. “AI allows us to streamline, focus on the most promising domains, and set ourselves up for success.”

AI in Protein Discovery at a Glance

• AlphaFold: Predicts protein structures, revealing which regions are stable and potentially druggable.
• Virtual Screening: Uses models to test thousands of compounds against predicted pockets in silico before moving to the lab.
• HDX-MS Integration: Measures how proteins move in solution, feeding real-world dynamics into machine learning models.
• Outcome: Faster, cheaper prioritization of compounds that are more likely to succeed in binding assays and, ultimately, clinical trials.

Tackling Gaps Where Current Therapies Fall Short

Lyterian’s pipeline is deliberately tuned to areas with poor treatment options. Alzheimer’s disease and ALS exemplify this: both lack effective small molecules that restore protein homeostasis.

“Most available treatments are antibodies or antisense oligonucleotides,” Wertz explains. “They require infusions or intrathecal delivery. If you can replace that with a pill, accessibility increases dramatically.”

Accessibility isn’t just about convenience; it’s about equity. In many parts of the world, infusion centers are rare, and manufacturing complex biologics is expensive. Lyterian’s small-molecule approach could make disease-modifying therapies possible in places where today they are out of reach.

Why Oral Delivery Matters

• Convenience: Oral pills reduce the burden of hospital visits and infusions.
• Scalability: Small molecules are easier to manufacture at scale compared to biologics.
• Equity: Patients in low-resource settings gain access to therapies that would otherwise be impractical.
• Compliance: Oral dosing improves adherence, critical in chronic diseases like Alzheimer’s or ALS.

The Patient-Focused Roadmap: From Lab Bench to Clinic

For readers new to drug development, Lyterian’s approach can be seen as a roadmap:

1. Pinpoint disease drivers through human genetic and clinical validation.
2. Design ligands that bind proteins of interest or recruit them to protein Z.
3. Screen libraries for glue-like properties and unexpected interactions.
4. Use AI and structural tools to refine targets and prioritize druggable domains.
5. Advance oral, accessible molecules for diseases with limited existing therapies.
6. Pursue partnerships to complement capabilities and accelerate clinical entry.

Partnerships: Beyond Capital, Toward Thought Collaboration

While fundraising is always a reality, Wertz emphasizes that Lyterian is looking for more than money. “We want thought partners,” she says. “Investors and collaborators who share our mission, contribute ideas, and complement what we do well.”

The company already works with academic labs, CROs in China and India, and small to mid-sized biotech partners. It is also in discussions with large pharma players. What matters most, Wertz stresses, is complementarity: when one side’s strength fills the other’s gap.

Asia’s Aging Populations and the Global Lens

In Taipei, where Wertz recently presented at a healthcare conference, the conversations highlighted a major reality: Asia’s aging populations face rising burdens of neurodegeneration. Alzheimer’s, ALS, and other conditions are set to grow rapidly, creating demand for therapies that are effective, scalable, and accessible.

“We need to understand not just what diseases are prevalent, but what treatments are already in use and where resistance or unmet needs remain,” Wertz reflects. In some cases, a therapy that seems redundant in the U.S. may be highly valuable in Asia, depending on local standards of care.

This perspective reinforces Lyterian’s global ambition: to build therapies that can reach patients everywhere, not just in elite clinics.

Collaboration as a Scientific Philosophy

Beyond business strategy, Wertz speaks with enthusiasm about collaboration itself. Her formative experience was working on venetoclax as a young scientist, an experience she still holds up as a gold standard.

“My favorite type of science is collaborative science,” she says. “When it works, one plus one really can equal three. You take best practices from different places and end up with something better than anyone could have done alone.”

Looking Ahead: Promise and Pragmatism

Lyterian is still young, and Wertz is clear-eyed about the challenges ahead. Developing a new class of therapeutics is expensive, slow, and full of uncertainty. Yet by grounding discovery in genetic validation, focusing on accessible small molecules, and building collaborations across borders, Lyterian has carved a patient-focused niche in one of biotech’s most competitive arenas.

“We’re showing that our platform can work across multiple targets,” Wertz concludes. “That emboldens us to reach out for partnerships, scale our impact, and move closer to the clinic.”

For professionals in oncology, neurodegeneration, and drug discovery, Lyterian represents not just a startup story but a test case for the next generation of therapeutics—where molecular glues, AI, and global collaboration converge to tackle diseases once thought intractable.

Author

Bernice Lottering